to study search History

Surgery for adenocarcinoma of the gastroesophageal junction (GEJ) type II: Transthoracic esophagectomy vs. transhiatal extended gastrectomy.

Organizational Data

DRKS-ID:
DRKS00016923
Recruitment Status:
Recruiting ongoing
Date of registration in DRKS:
2019-08-02
Last update in DRKS:
2021-01-27
Registration type:
Prospective

Acronym/abbreviation of the study

CARDIA Trial

URL of the study

No Entry

Brief summary in lay language

The CARDIA study examines malignant tumors located directly at the transition between the esophagus and stomach. By surgically removing the tumour, this cancer can be cured in some of the affected patients. There are currently two possible surgical procedures. One procedure is the transthoracic oesophagectomy with stomach elevation. During this procedure, a large part of the oesophagus is removed together with the oesophageal-gastric-transition. The stomach is then formed into a tube and connected to the rest of the esophagus in the chest cavity. The other operation is the transhiatal extended gastrectomy. In this procedure, the stomach is removed together with the oesophageal-gastric-transition. A connection is then created between the esophagus and a part of the small intestine. Both procedures allow complete removal of the tumor. However, they are associated with different risks and complications. So far, it has not been possible to determine scientifically which of the two operations is better suited for the treatment of transitional tumors. The aim of this clinical study is therefore to compare the two procedures in terms of healing rates and the resulting quality of life.

Brief summary in scientific language

Adenocarcinomas of the gastroesophageal Junction (GEJ) type II can be resected either by transthoracic oesophageectomy or transhiatal extended gastrectomy. Both surgical procedures allow a complete tumor resection. To date, it has not been determined which surgery is superior in terms of quality of life, oncological outcome and survival, as only retrospective studies with contradictory results have been conducted so far. The CARDIA trial compares both surgical procedures in a non-blinded, multinational, multicenter, prospectively randomized study design. Patients with an GEJ type II tumor that can be resected by both transthoracic esophagectomy and transhiatal gastrectomy will be enrolled in the trial and will be operated after randomization using one of the investigated surgical procedure. Primary endpoint is overall survival. Secondary endpoints are complete resection (R0), number and location of tumor-infiltrated lymph nodes, postoperative complications, disease-free survival, quality of life and cost-effectiveness. Postoperative survival, disease-free survival and quality of life are monitored for 24 months after discharge. Overall survival is then monitored through quarterly telephone calls up to 60 months after surgery.

Health condition or problem studied

ICD10:
C16.0 - Cardia
Healthy volunteers:
No Entry

Interventions, Observational Groups

Arm 1:
Transthoracic esophagectomy (removal of the esophagus and intrathoracic connection of the esophagus to the stomach)
Arm 2:
Transhiatal extended gastrectomy (Removal of the stomach and the lower part of the esophagus with esophageal jejunostomy)

Endpoints

Primary outcome:
Overall survival (Follow-up up to 60 months after discharge)
Secondary outcome:
Complete (R0) resection, post-operative complications according to the Dindo-Clavien classification, number and Tumor Infiltration of lymph nodes at dissection, quality of life (EORTC QLQ-C30, -STO22, -OG25 after 3, 6, 12, 18, 24 months), cost-effectiveness

Study Design

Purpose:
Treatment
Allocation:
Randomized controlled study
Control:
  • Active control (effective treatment of control group)
Phase:
IV
Study type:
Interventional
Mechanism of allocation concealment:
No Entry
Blinding:
No
Assignment:
Parallel
Sequence generation:
No Entry
Who is blinded:
No Entry

Recruitment

Recruitment Status:
Recruiting ongoing
Reason if recruiting stopped or withdrawn:
No Entry

Recruitment Locations

Recruitment countries:
  • Germany
  • Netherlands
Number of study centers:
Multicenter study
Recruitment location(s):
  • University medical center Universitätsklinik Köln Köln

Recruitment period and number of participants

Planned study start date:
2019-09-01
Actual study start date:
2020-04-16
Planned study completion date:
No Entry
Actual Study Completion Date:
No Entry
Target Sample Size:
262
Final Sample Size:
No Entry

Inclusion Criteria

Sex:
All
Minimum Age:
18 Years
Maximum Age:
no maximum age
Additional Inclusion Criteria:
• Histologically proven adenocarcinoma of the GEJ type II • Non-metastatic tumor, resectable by both transthoracic esophagectomy and transhiatal extended gastrectomy according to the local surgical investigator • Age ≥ 18 • ECOG Eastern Cooperative Oncology Group (ECOG) performance status 0–2 • ASA < 4. • Pre-treatment stage cT1-4a N0/N+, M0 • In case of stage cT4a, curative resectability must be explicitly verified by the local surgical investigator prior to randomization • Patients with locally advanced tumors (T3-T4 or N+) who received four cycles of chemotherapy (FLOT) preoperatively • Negative serum pregnancy test during screening period for women of child-bearing age • Patients with a cardiac history should receive a cardiology consultation and should have a left ventricular ejection fraction > 50% (determined by echocardiography) • Adequate respiratory function (pulmonary function tests only necessary in symptomatic patients) with FEV1>/= 1.5 l/s • Adequate bone marrow function (white blood cells > 3x10^9 /l; hemoglobin > 9 g/dl; platelets > 100x10^9 /l), renal function (glomerular filtration rate >60 ml/min), and liver function (total bilirubin < 1.5x upper level of normal (ULN), aspartate transaminase (AST) < 2.5x ULN and alanine transaminase (ALT) < 3x ULN) • Written informed consent

Exclusion Criteria

• Tumors of squamous, adenosquamous or another non-adenocarcinoma histology • Advanced inoperable or metastatic GEJ type II adenocarcinoma • GEJ type II adenocarcinoma staged cT4b, M+ • GEJ type II cT4a evaluated as not curatively resectable by the local surgical investigator • Histologically proven adenocarcinoma of the GEJ type I and III • Severe tumor stenosis preventing endoscopic tumor classification • Tumor expanding more than 5 cm proximal of the GEJ • Tumor resectable only by transthoracic esophagectomy or only by transhiatal extended gastrectomy, according to the local surgical investigator • Positive lymph nodes only resectable by transthoracic esophagectomy (i.e. in the mid-upper mediastinum) or only resectable by transhiatal extended gastrectomy according to the local surgical investigator. • Patients with locally advanced tumors (T3-T4 or N+) who did not receive chemotherapy (FLOT) preoperatively or received more or less than the allowed 4 cycles of chemotherapy • Clinically significant (active) cardiac disease (e.g. symptomatic coronary artery disease or myocardial infarction within last 12 months) • Clinically significant lung disease (forced expiratory volume in one second (FEV1) < 1.5 l/s) • Pregnant women and nursing mothers • Persons with any kind of dependency on the principal investigator or employed by the sponsor or principal investigator • Legally incapacitated persons • Persons held in an institution by legal or official order

Addresses

Primary Sponsor

Universitätsklinik Köln Klinik und Poliklinik für Allgemein- Viszeral- und Tumorchirurgie
Prof. Dr. Christiane Bruns
Kerpener Str. 62
50937 Köln
Germany
Telephone:
+49-221-478-4801
Fax:
No Entry
Contact per E-Mail
URL:
No Entry
Investigator Sponsored/Initiated Trial (IST/IIT):
Yes

Contact for Scientific Queries

Universitätsklinik Köln Klinik und Poliklinik für Allgemein- Viszeral- und Tumorchirurgie
Prof. Dr. Christiane Bruns
Kerpener Str. 62
50937 Köln
Germany
Telephone:
+49-221-478-4801
Fax:
No Entry
Contact per E-Mail
URL:
No Entry

Contact for Public Queries

Universitätsklinik Köln Klinik und Poliklinik für Allgemein- Viszeral- und Tumorchirurgie
Prof. Dr. Christiane Bruns
Kerpener Str. 62
50937 Köln
Germany
Telephone:
+49-221-478-4801
Fax:
No Entry
Contact per E-Mail
URL:
No Entry

Principal Investigator

Universitätsklinik Köln Klinik und Poliklinik für Allgemein- Viszeral- und Tumorchirurgie
Prof. Dr. Christiane Bruns
Kerpener Str. 62
50937 Köln
Germany
Telephone:
+49-221-478-4801
Fax:
No Entry
Contact per E-Mail
URL:
No Entry

Sources of Monetary or Material Support

Public funding institutions financed by tax money/Government funding body (German Research Foundation (DFG), Federal Ministry of Education and Research (BMBF), etc.)

Bundesministerium für Bildung und Forschung Dienstsitz Berlin
Friedrichstraße 130 B
10117 Berlin
Germany
Telephone:
No Entry
Fax:
No Entry
Contact per E-Mail
URL:
http://www.bmbf.de

Ethics Committee

Address Ethics Committee

Ethikkommission der Medizinischen Fakultät der Universität zu Köln
Gleueler Str. 269
50935 Köln
Germany
Telephone:
+49-221-478 82900
Fax:
+40-221-478 82905
Contact per E-Mail
URL:
No Entry

Vote of leading Ethics Committee

Date of ethics committee application:
2019-07-24
Ethics committee number:
19-1376
Vote of the Ethics Committee:
Approved
Date of the vote:
2019-08-30

Further identification numbers

Other primary registry ID:
No Entry
EudraCT Number:
No Entry
UTN (Universal Trial Number):
No Entry
EUDAMED Number:
No Entry

IPD - Individual Participant Data

Do you plan to make participant-related data (IPD) available to other researchers in an anonymized form?:
No
IPD Sharing Plan:
No Entry

Study protocol and other study documents

Study protocols:
No Entry
Study abstract:
No Entry
Other study documents:
No Entry
Background literature:
No Entry
Related DRKS studies:
No Entry

Publication of study results

Planned publication:
No Entry
Publikationen/Studienergebnisse:
No Entry
Date of first publication of study results:
No Entry
DRKS entry published for the first time with results:
No Entry

Basic reporting

Basic Reporting / Results tables:
No Entry
Brief summary of results:
No Entry